Skip to main content
Top
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line

Authors: Takahiro Yamauchi, Kanako Uzui, Rie Nishi, Hiroko Shigemi, Takanori Ueda

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Nine-beta-D-arabinofuranosylguanine (ara-G), an active metabolite of nelarabine, enters leukemic cells through human Equilibrative Nucleoside Transporter 1, and is then phosphorylated to an intracellular active metabolite ara-G triphosphate (ara-GTP) by both cytosolic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Ara-GTP is subsequently incorporated into DNA, thereby inhibiting DNA synthesis.

Methods

In the present study, we developed a novel ara-G-resistant variant (CEM/ara-G) of human T-lymphoblastic leukemia cell line CCRF-CEM, and elucidated its mechanism of ara-G resistance. The cytotoxicity was measured by using the growth inhibition assay and the induction of apoptosis. Intracellular triphosphate concentrations were quantitated by using HPLC. DNA synthesis was evaluated by the incorporation of tritiated thymidine into DNA. Protein expression levels were determined by using Western blotting.

Results

CEM/ara-G cells were 70-fold more ara-G-resistant than were CEM cells. CEM/ara-G cells were also refractory to ara-G-mediated apoptosis. The transcript level of human Equilibrative Nucleoside Transporter 1 was lowered, and the protein levels of deoxycytidine kinase and deoxyguanosine kinase were decreased in CEM/ara-G cells. The subsequent production of intracellular ara-GTP (21.3 pmol/107 cells) was one-fourth that of CEM cells (83.9 pmol/107 cells) after incubation for 6 h with 10 μM ara-G. Upon ara-G treatment, ara-G incorporation into nuclear and mitochondrial DNA resulted in the inhibition of DNA synthesis of both fractions in CEM cells. However, DNA synthesis was not inhibited in CEM/ara-G cells due to reduced ara-G incorporation into DNA. Mitochondrial DNA-depleted CEM cells, which were generated by treating CEM cells with ethidium bromide, were as sensitive to ara-G as CEM cells. Anti-apoptotic Bcl-xL was increased and pro-apoptotic Bax and Bad were reduced in CEM/ara-G cells.

Conclusions

An ara-G-resistant CEM variant was successfully established. The mechanisms of resistance included reduced drug incorporation into nuclear DNA and antiapoptosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Faderl S, Gandhi V, Kantarjian H, Plunkett W: New nucleoside analogues in clinical development. Cancer Chemother Biol Response Modif. 2002, 20: 37-58.PubMed Faderl S, Gandhi V, Kantarjian H, Plunkett W: New nucleoside analogues in clinical development. Cancer Chemother Biol Response Modif. 2002, 20: 37-58.PubMed
3.
go back to reference Ghanem H, Kantarjian H, Ohanian M, Jabbour E: The role of clofarabine in acute myeloid leukemia. Leuk Lymphoma. 2013, 54: 688-698.CrossRefPubMed Ghanem H, Kantarjian H, Ohanian M, Jabbour E: The role of clofarabine in acute myeloid leukemia. Leuk Lymphoma. 2013, 54: 688-698.CrossRefPubMed
4.
go back to reference Cohen MH, Johnson JR, Massie T, Sridhara R, McGuinn WD, Abraham S, Booth BP, Goheer MA, Morse D, Chen XH, Chidambaram N, Kenna L, Gobburu JV, Justice R, Pazdur R: Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin Cancer Res. 2006, 12: 5329-5335.CrossRefPubMed Cohen MH, Johnson JR, Massie T, Sridhara R, McGuinn WD, Abraham S, Booth BP, Goheer MA, Morse D, Chen XH, Chidambaram N, Kenna L, Gobburu JV, Justice R, Pazdur R: Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin Cancer Res. 2006, 12: 5329-5335.CrossRefPubMed
5.
go back to reference Gandhi V, Plunkett W: Clofarabine and nelarabine: two new purine nucleoside analogs. Curr Opin Oncol. 2006, 18: 584-590.CrossRefPubMed Gandhi V, Plunkett W: Clofarabine and nelarabine: two new purine nucleoside analogs. Curr Opin Oncol. 2006, 18: 584-590.CrossRefPubMed
6.
go back to reference Ravandi F, Gandhi V: Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma. Expert Opin Investig Drugs. 2006, 15: 1601-1613.CrossRefPubMed Ravandi F, Gandhi V: Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma. Expert Opin Investig Drugs. 2006, 15: 1601-1613.CrossRefPubMed
7.
go back to reference DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, Gockerman JP, Mitchell BS, Appelbaum FR, Larson RA: Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: cancer and leukemia group B study 19801. Blood. 2007, 109: 5136-5142.CrossRefPubMedPubMedCentral DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, Gockerman JP, Mitchell BS, Appelbaum FR, Larson RA: Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: cancer and leukemia group B study 19801. Blood. 2007, 109: 5136-5142.CrossRefPubMedPubMedCentral
8.
go back to reference Rodriguez CO, Gandhi V: Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step. Cancer Res. 1999, 59: 4937-4943.PubMed Rodriguez CO, Gandhi V: Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step. Cancer Res. 1999, 59: 4937-4943.PubMed
9.
go back to reference Rodriguez CO, Mitchell BS, Ayres M, Eriksson S, Gandhi V: Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res. 2002, 62: 3100-3105.PubMed Rodriguez CO, Mitchell BS, Ayres M, Eriksson S, Gandhi V: Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res. 2002, 62: 3100-3105.PubMed
10.
go back to reference Rodriguez CO, Stellrecht CM, Gandhi V: Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood. 2003, 102: 1842-1848.CrossRefPubMed Rodriguez CO, Stellrecht CM, Gandhi V: Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood. 2003, 102: 1842-1848.CrossRefPubMed
11.
go back to reference Gandhi V, Mineishi S, Huang P, Yang Y, Chubb S, Chapman AJ, Nowak BJ, Hertel LW, Plunkett W: Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells. Semin Oncol. 1995, 22 (4 Suppl 11): 61-67.PubMed Gandhi V, Mineishi S, Huang P, Yang Y, Chubb S, Chapman AJ, Nowak BJ, Hertel LW, Plunkett W: Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells. Semin Oncol. 1995, 22 (4 Suppl 11): 61-67.PubMed
12.
go back to reference Prus KL, Averett DR, Zimmerman TP: Transport and metabolism of 9-β-D-arabinofuranosylguanine in a human T-lymphoblastoid cell line: nitrobenzylthioinosine-sensitive and –insensitive influx. Cancer Res. 1990, 50: 1817-1821.PubMed Prus KL, Averett DR, Zimmerman TP: Transport and metabolism of 9-β-D-arabinofuranosylguanine in a human T-lymphoblastoid cell line: nitrobenzylthioinosine-sensitive and –insensitive influx. Cancer Res. 1990, 50: 1817-1821.PubMed
13.
go back to reference Shigemi H, Yamauchi T, Tanaka Y, Yokota Y, Ueda T: Establishment of novel leukemic cell lines resistant to clofarabine by dual mechanisms of decreased intracellular active metabolite and increased antiapoptotic factor. Cancer Sci. 2013, 104: 732-739.CrossRefPubMed Shigemi H, Yamauchi T, Tanaka Y, Yokota Y, Ueda T: Establishment of novel leukemic cell lines resistant to clofarabine by dual mechanisms of decreased intracellular active metabolite and increased antiapoptotic factor. Cancer Sci. 2013, 104: 732-739.CrossRefPubMed
14.
go back to reference Yamauchi T, Nishi R, Kitazumi K, Nakano T, Ueda T: A new high-performance liquid chromatography method determines low production of 9-beta-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells. Oncol Rep. 2010, 23: 499-504.PubMed Yamauchi T, Nishi R, Kitazumi K, Nakano T, Ueda T: A new high-performance liquid chromatography method determines low production of 9-beta-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells. Oncol Rep. 2010, 23: 499-504.PubMed
15.
go back to reference Yamauchi T, Negoro E, Kishi S, Takagi K, Yoshida A, Urasaki Y, Iwasaki H, Ueda T: Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5′-nucleotidase II expression ratio in primary acute myeloid leukemia cells. Biochem Pharmacol. 2009, 77: 1780-1786.CrossRefPubMed Yamauchi T, Negoro E, Kishi S, Takagi K, Yoshida A, Urasaki Y, Iwasaki H, Ueda T: Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5′-nucleotidase II expression ratio in primary acute myeloid leukemia cells. Biochem Pharmacol. 2009, 77: 1780-1786.CrossRefPubMed
16.
go back to reference Yamauchi T, Ueda T: A sensitive new method for clinically monitoring cytarabine concentrations at the DNA level in leukemic cells. Biochem Pharmacol. 2005, 69: 1795-1803.CrossRefPubMed Yamauchi T, Ueda T: A sensitive new method for clinically monitoring cytarabine concentrations at the DNA level in leukemic cells. Biochem Pharmacol. 2005, 69: 1795-1803.CrossRefPubMed
17.
go back to reference Yamauchi T, Nowak BJ, Keating MJ, Plunkett W: DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res. 2001, 7: 3580-3589.PubMed Yamauchi T, Nowak BJ, Keating MJ, Plunkett W: DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res. 2001, 7: 3580-3589.PubMed
18.
go back to reference Yamauchi T, Keating MJ, Plunkett W: UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes. Mol Cancer Ther. 2002, 1: 287-294.CrossRefPubMed Yamauchi T, Keating MJ, Plunkett W: UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes. Mol Cancer Ther. 2002, 1: 287-294.CrossRefPubMed
19.
go back to reference Park KS, Nam KJ, Kim JW, Lee YB, Han CY, Jeong JK, Lee HK, Pak YK: Depletion of mitochondrial DNA alters glucose metabolism in SK-Hep1 cells. Am J Physiol Endocrinol Metab. 2001, 280: E1007-E1014.PubMed Park KS, Nam KJ, Kim JW, Lee YB, Han CY, Jeong JK, Lee HK, Pak YK: Depletion of mitochondrial DNA alters glucose metabolism in SK-Hep1 cells. Am J Physiol Endocrinol Metab. 2001, 280: E1007-E1014.PubMed
20.
go back to reference Yamauchi T, Ueda T, Nakamura T: A new sensitive method for determination of intracellular 1-β-D-arabinofuranosylcytosine 5′-triphosphate content in human materials in vivo. Cancer Res. 1996, 56: 1800-1804.PubMed Yamauchi T, Ueda T, Nakamura T: A new sensitive method for determination of intracellular 1-β-D-arabinofuranosylcytosine 5′-triphosphate content in human materials in vivo. Cancer Res. 1996, 56: 1800-1804.PubMed
21.
go back to reference Yamamoto S, Yamauchi T, Kawai Y, Takemura H, Kishi S, Yoshida A, Urasaki Y, Iwasaki H, Ueda T: Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells. Int J Hematol. 2007, 85: 108-115.CrossRefPubMed Yamamoto S, Yamauchi T, Kawai Y, Takemura H, Kishi S, Yoshida A, Urasaki Y, Iwasaki H, Ueda T: Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells. Int J Hematol. 2007, 85: 108-115.CrossRefPubMed
22.
go back to reference Huang P, Plunkett W: Fludarabine- and gemcitabine- induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol. 1995, 36: 181-188.CrossRefPubMed Huang P, Plunkett W: Fludarabine- and gemcitabine- induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol. 1995, 36: 181-188.CrossRefPubMed
23.
go back to reference Huang P, Robertson LE, Wright S, Plunkett W: High molecular weight DNA fragmentation: a critical event in nucleoside analogue-induced apoptosis in leukemia cells. Clin Cancer Res. 1995, 1: 1005-1013.PubMed Huang P, Robertson LE, Wright S, Plunkett W: High molecular weight DNA fragmentation: a critical event in nucleoside analogue-induced apoptosis in leukemia cells. Clin Cancer Res. 1995, 1: 1005-1013.PubMed
24.
go back to reference Jacobson MD, Burne JF, King MP, Miyashita T, Reed JC, Raff MC: Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature. 1993, 361: 365-369.CrossRefPubMed Jacobson MD, Burne JF, King MP, Miyashita T, Reed JC, Raff MC: Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature. 1993, 361: 365-369.CrossRefPubMed
25.
go back to reference Marchetti P, Susin SA, Decaudin D, Gamen S, Castedo M, Hirsch T, Zamzami N, Naval J, Senik A, Kroemer G: Apoptosis-associated derangement of mitochondrial function in cells lacking mitochondrial DNA. Cancer Res. 1996, 56: 2033-2038.PubMed Marchetti P, Susin SA, Decaudin D, Gamen S, Castedo M, Hirsch T, Zamzami N, Naval J, Senik A, Kroemer G: Apoptosis-associated derangement of mitochondrial function in cells lacking mitochondrial DNA. Cancer Res. 1996, 56: 2033-2038.PubMed
26.
go back to reference Liang BC, Ullyatt E: Increased sensitivity to cis-diamminedichloroplatinum induced apoptosis with mitochondrial DNA depletion. Cell Death Differ. 1998, 5: 694-701.CrossRefPubMed Liang BC, Ullyatt E: Increased sensitivity to cis-diamminedichloroplatinum induced apoptosis with mitochondrial DNA depletion. Cell Death Differ. 1998, 5: 694-701.CrossRefPubMed
27.
go back to reference Jiang S, Cai J, Wallace DC, Jones DP: Cytochrome c-mediated apoptosis in cells lacking mitochondrial DNA. Signaling pathway involving release and caspase 3 activation is conserved. J Biol Chem. 1999, 274: 29905-29911.CrossRefPubMed Jiang S, Cai J, Wallace DC, Jones DP: Cytochrome c-mediated apoptosis in cells lacking mitochondrial DNA. Signaling pathway involving release and caspase 3 activation is conserved. J Biol Chem. 1999, 274: 29905-29911.CrossRefPubMed
28.
go back to reference Pelicano H, Xu RH, Du M, Feng L, Sasaki R, Carew JS, Hu Y, Ramdas L, Hu L, Keating MJ, Zhang W, Plunkett W, Huang P: Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol. 2006, 175: 913-923.CrossRefPubMedPubMedCentral Pelicano H, Xu RH, Du M, Feng L, Sasaki R, Carew JS, Hu Y, Ramdas L, Hu L, Keating MJ, Zhang W, Plunkett W, Huang P: Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol. 2006, 175: 913-923.CrossRefPubMedPubMedCentral
29.
go back to reference Shewach DS, Daddona PE, Ashcraft E, Mitchell BS: Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts. Cancer Res. 1985, 45: 1008-1014.PubMed Shewach DS, Daddona PE, Ashcraft E, Mitchell BS: Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts. Cancer Res. 1985, 45: 1008-1014.PubMed
30.
go back to reference Curbo S, Zhu C, Johansson M, Balzarini J, Karlsson A: Dual mechanisms of 9-β-D-arabinofuranosylguanine resistance in CEM T-Lymphoblast Leukemia cells. Biochem Biophys Res Com. 2001, 285: 40-45.CrossRefPubMed Curbo S, Zhu C, Johansson M, Balzarini J, Karlsson A: Dual mechanisms of 9-β-D-arabinofuranosylguanine resistance in CEM T-Lymphoblast Leukemia cells. Biochem Biophys Res Com. 2001, 285: 40-45.CrossRefPubMed
31.
go back to reference Curbo S, Zhivotovsky B, Johansson M, Karlsson A: Effects of 9-β-D-arabinofuranosylguanine on mitochondria in CEM T-lymphoblast leukemia cells. Biochem Biophys Res Com. 2003, 307: 942-947.CrossRefPubMed Curbo S, Zhivotovsky B, Johansson M, Karlsson A: Effects of 9-β-D-arabinofuranosylguanine on mitochondria in CEM T-lymphoblast leukemia cells. Biochem Biophys Res Com. 2003, 307: 942-947.CrossRefPubMed
32.
go back to reference Curbo S, Johansson M, Balzarini J, Lewis LD, Karlsson A: Acute cytotoxicity of arabinofuranosyl nucleoside analogs is not dependent on mitochondrial DNA. Exp Cell Res. 2009, 315: 2539-2543.CrossRefPubMed Curbo S, Johansson M, Balzarini J, Lewis LD, Karlsson A: Acute cytotoxicity of arabinofuranosyl nucleoside analogs is not dependent on mitochondrial DNA. Exp Cell Res. 2009, 315: 2539-2543.CrossRefPubMed
33.
go back to reference Lotfi K, Månsson E, Peterson C, Eriksson S, Albertioni F: Low level of mitochondrial deoxyguanosine kinase is the dominant factor in acquired resistance to 9-β-D-arabinofuranosylguanine cytotoxicity. Biochem Biophys Res Com. 2002, 293: 1489-1496.CrossRefPubMed Lotfi K, Månsson E, Peterson C, Eriksson S, Albertioni F: Low level of mitochondrial deoxyguanosine kinase is the dominant factor in acquired resistance to 9-β-D-arabinofuranosylguanine cytotoxicity. Biochem Biophys Res Com. 2002, 293: 1489-1496.CrossRefPubMed
34.
go back to reference Månsson E, Stridh H, Albertioni F: Resistance to mitochondrial- and Fas-mediated apoptosis in human leukemic cells with acquired resistance to 9-β-D-arabinofuranosylguanosine. Biochem Biophys Res Com. 2002, 298: 338-344.CrossRefPubMed Månsson E, Stridh H, Albertioni F: Resistance to mitochondrial- and Fas-mediated apoptosis in human leukemic cells with acquired resistance to 9-β-D-arabinofuranosylguanosine. Biochem Biophys Res Com. 2002, 298: 338-344.CrossRefPubMed
35.
go back to reference Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ: Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol. 1985, 12 (suppl. 3): 20-30.PubMed Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ: Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol. 1985, 12 (suppl. 3): 20-30.PubMed
36.
go back to reference Estey EH: Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia. 2000, 14: 476-479.CrossRefPubMed Estey EH: Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia. 2000, 14: 476-479.CrossRefPubMed
Metadata
Title
Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line
Authors
Takahiro Yamauchi
Kanako Uzui
Rie Nishi
Hiroko Shigemi
Takanori Ueda
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-547

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine